Table 1.
Patient 1 | Patient 2 | |
---|---|---|
Demographics | ||
Age (years) | 26 | 29 |
Sex | F | M |
Ethnicity | Hispanic | Hispanic |
Underlying medical conditions | ||
Asthma | Yes | No |
Diabetes | No | No |
Immunocompromised | No | No |
Chronic cardiovascular disease | No | No |
Chronic renal disease | No | No |
Neurocognitive disorder | No | No |
Neuromuscular disorder | No | No |
Other prior neurological conditions | No | No |
Pregnancy | No | N/A |
Seizure disorder | No | No |
Other prior medical conditions | Gastroesophageal reflux | Malaria |
Prior medications | Fluticasone, salmeterol, montelukast, nabumetone, omeprazole, albuterol, prednisone taper | None |
Allergies | NKDA | NKDA |
Ever a smoker | Yes (current) | No |
BMI | 66 | 31 |
ASA therapy | No | No |
Clinical symptoms at presenting admission | ||
Fever | Yes | Yes |
Cough | Yes | Yes |
Shortness of breath | Yes | Yes |
Fatigue/weakness | Yes | Yes |
Chills | Yes | No |
Rhinorrhea | Yes | Yes |
Myalgias | Yes | Yes |
Headache | No | Yes |
Sore throat | Yes | Yes |
Vomiting | No | Yes |
Wheezing | Yes | No |
Diarrhea | No | No |
Presence of neurological signs/symptoms at admission | No | No |
Presenting admission laboratory data | ||
Serum sodium (mmol/L) | 134 | 136 |
Liver function tests | Elevated | Elevated |
Blood bacterial culture | Negative | Negative |
Urine bacterial culture | Negative | Negative |
Viral testing and antiviral therapy | ||
H1N1 reverse transcriptase–polymerase chain reaction positive | Yes | Yes |
Hospitalization results | ||
Length of hospitalization (days) | 11 | 8 days |
Selected laboratory abnormalities during hospitalization | ||
Sodium (Na) nadir (mmol/L) | 123 | 123 |
Na at time of neurological presentation (mmol/L) | 126 | 126 |
Neurologic presentation | ||
Neurologic complication(s) diagnosed | Cerebral edema | Cerebral edema |
Interval from respiratory illness onset to neurologic symptoms (days) | 3 | >1 week |
Intracranial pressure at time of neurologic presentation (cm CSF) | 26 | N/A |
Plasma creatinine at time of neurological presentation (mg/dL) | 3.93 | 5.81 |
Creatine kinase at time of neurological presentation (U/L) | 4868 | 2935 |
Neurodiagnostic testing | ||
Head CT scan | Cerebral edema | Cerebral edema |
Brain MRI | No (obese – unable to fit in scanner) | No (patient not stable for travel) |
Placement of ICP monitoring device | EVD | None |
ASA = aminosalicylic acid, BMI = body mass index, CSF = cerebrospinal fluid, EVD = external ventricular drain, N/A = not applicable, NKDA = no known drug allergies.